Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Date:3/26/2008

the quarter ended December 31, 2007, were $9.0 million, with $7.6 million attributable to research and development. This compares to operating expenses of $15.0 million and research and development expenses of $4.7 million for the same period last year. The Company reported a net loss for the quarter ended December 31, 2007, of $8.2 million, compared to a net loss of $13.1 million for the same period last year.

Revenue for the full year ended December 31, 2007, was $9.9 million compared to revenue of $9.9 million for the same period in 2006. Operating expenses for the 12-month period were $33.6 million, with $28.0 million attributable to research and development. This compares to operating expenses of $34.7 million and research and development expenses of $22.4 million for the same 12-month period last year. The Company reported a net loss for the year ended December 31, 2007, of $23.4 million compared to a net loss of $25.4 million for the same period last year.

For 2008, management has indicated that it is targeting a net cash burn in the range of $22.0 million to $24.0 million.

TorreyPines' complete fiscal 2007 annual report will be available on TorreyPines' Web site: http://www.torreypinestherapeutics.com. Go to the investor center then click on SEC filings.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates, two ionotropic glutamate receptor antagonists and two mu
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
2. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. TorreyPines Therapeutics Reports Third Quarter 2007 Results
4. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
8. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
9. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
10. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
11. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Global & USA BioSimilar Market Analysis to 2021" ... US Biosimilar market will be initiated in September as ... will the global market react? Will biosimilars explode into ... save the US economy up to $250 billion within ...
(Date:8/28/2015)... , August 28, 2015 According ... (Media, Sera, Cryogenic Storage Systems, Thawing Equipment, Alarms), by ... Medicine, Clinical Trials), End User - Global Forecast to ... expected to reach USD 3,731.03 Million by 2020 from ... of 11.65% between 2015 and 2020. ...
(Date:8/28/2015)... ... August 28, 2015 , ... Proove Biosciences ... the International Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). ... 2015. With a focus on evidence-based research and clinical application, the event gathered ...
(Date:8/28/2015)... ... August 28, 2015 , ... Pittcon is ... will present a session on chemical spectroscopic imaging at JASIS 2015 (Japan Analytical ... Asia’s largest analytical and scientific instruments show which will be held at International ...
Breaking Biology Technology:Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3
... CHENGDU, China, Sept. 17 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical, Co., Inc., ... of,modernized traditional Chinese medicine (,TCM,) based in Chengdu, China, ... discuss its fiscal,2009 fourth quarter and full year results ... Interested parties may access the ...
... ... liquid medications, pharmacists are prepared to help children successfully take antiviral medications to fight the ... children are more likely to take their medicine as prescribed. , ... Columbia, MD, (PRWEB) September 17, 2009 -- As new ...
... ... software industries, among others , ... Boston, Massachusetts (Vocus) -- Brown Rudnick, an international law firm, today announced ... the Firm,s Boston office. With over 35 years of combined experience, the team includes ...
Cached Biology Technology:Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET 2FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 2FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 3FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 4Veteran Intellectual Property Team Joins Brown Rudnick 2
(Date:8/28/2015)... 2015 According to a new ... Assessment Type (Pen & Paper Based, Hosted, Biometrics), Service, ... Academic Research), Vertical and Region - Global Forecast to ... to grow from USD 2.4 Billion in 2015 to ... Growth Rate (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/26/2015)... 2015 The report "Multi-Factor Authentication (MFA) ... Application (Travel & Immigration, Government, Banking, Defense, Commercial Security, ... 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is expected ... a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ages ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015  Sarcos ... today it will unveil its "Guardian S" snake robot, ... National Tactical Officers Association Conference on August 30 in ... is the first-ever commercially available energetically autonomous snake robot, ... in-field trials and is protected by more than 50 ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
... WASHINGTON, DC, JULY 7, 2008 -- The Soil Science ... by Senator Sherrod Brown and his colleagues in the ... as an "essential" natural resource, placing soil on par ... Brown was joined by co-sponsoring Senators Kent Conrad (D-ND), ...
... of cancer continues to pose a major problem for ... of chemotherapy or become resistant to the medication. Scientists ... Braunschweig, the Hannover Medical School (MHH) and Leibniz-Universitt (LUH) ... which a natural substance - argyrin - destroys tumours. ...
... MADISON, WI, JULY 6, 2008 -- Swine production generates ... that may serve as fertilizer when applied to agricultural ... different than what a crop requires. Application of waste ... in application of excess phosphorus which increases the potential ...
Cached Biology News:Senate resolution shines spotlight on the importance of soils 2Argyrin: Natural substance raises hope for new cancer therapies 2